Author: HASAN BURHANETTİN KAPTI (Turkey)
Co-authors: SERKAN ÖZEN
Purpose
Macular oedema (MO) is characterized by the accumulation of extracellular fluid between the retinal layers. MO may be associated with many pathological conditions such as diabetic retinopathy, retinal vein occlusion and inflammatory diseases. Intravitreal dexamethasone implant (DEX; Ozurdex, Allergan, Irvine, CA, USA ) is widely used in MO treatment. It has been shown that the efficacy and half-life of intravitreal drugs are reduced due to increased drug clearance in vitrectomised eyes. Our aim is to compare the short-term results of intravitreal dexamethasone implant for retinal vein occlusion (RVO) in vitrectomised and non-vitrectomised eyes
Setting/Venue
Retrospective, consecutive, interventional case series / Ordu University, School of Medicine, Department of Ophtalmology
Methods
The records of 28 pseudophakic eyes with or without vitrectomy but receiving DEX for RVT after poor response to anti-vascular endothelial growth factor were analyzed retrospectively. Central macular thickness (CMT) measurement by optical coherence tomography, intraocular pressure (İOP) and best corrected visual acuity (BCVA) examinations were performed before , 1 and 3 months after implantation
Results
The BCVA, CMT and IOP measurements were evaluated to compare the effectiveness of the dexamethasone implant between the age and sex-matched vitrectomized group (12 eyes) and the non-vitrectomized group (16 eyes).In the nonvitrectomized group, logmar VA improved from mean 1.39 ± 0.27 at the beginning to 0.85 ± 0.18 and 1.05 ± 0.24 after 1 and 3 months, respectively. In the vitrectomized group, the initial logmar VA improved from mean 1.52 ± 0.41 to 1.11 ± 0.49 and 1.19 ± 0.43 after 1 and 3 months, respectively. In the non-vitrectomised group, the CMT was mean 666.75 ± 170.81 before DEX implantation, 244.75 ± 74.44 and 288 ± 62.44 after 1 and 3 months, respectively. In the vitrectomised group, the CMT was mean 662.25 ± 202.30, 380.25 ± 42.35, and 398.37 ± 100.98 at before, 1 and 3 months, respectively. In both groups, BCVA and CMT significantly improved at 1 and 3 months after DEX implantation. İOP increased in 2 eyes in the vitrectomized group and 3 eyes in the nonvitrectomized group. However, it was controlled with İOP lowering medication. There was no statistically significant difference in BCVA, CMT and İOP between the two treatment groups at any time point.
Conlusions
The short-term effectiveness of the DEX implant is not affected by previous vitrectomy surgeries in eyes with RVO. The effects on SMT, IOP and BCVA in the first 3 months were similar to eyes without vitrectomy. Studies evaluating the long-term effects of dexamethasone multiple injections in vitrectomized eyes will be guiding in this regard
Financial Disclosure
NONE
Comments
-
